摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

α-7-deoxyhomonojirimycin | 78821-35-9

中文名称
——
中文别名
——
英文名称
α-7-deoxyhomonojirimycin
英文别名
(2R,3R,4R,5S,6R)-2-(hydroxymethyl)-6-methylpiperidine-3,4,5-triol;alpha-7-Deoxyhomonojirimycin
α-7-deoxyhomonojirimycin化学式
CAS
78821-35-9
化学式
C7H15NO4
mdl
——
分子量
177.2
InChiKey
ZEWFPWKROPWRKE-XUUWZHRGSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.9
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    93
  • 氢给体数:
    5
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    聚合甲醛α-7-deoxyhomonojirimycin甲酸 作用下, 以 为溶剂, 反应 5.0h, 以84 mg的产率得到N-methyl-7-deoxy-α-homonojirimycin
    参考文献:
    名称:
    α-Glucosidase-inhibitory iminosugars from the leaves of Suregada glomerulata
    摘要:
    A water extract of the leaves of Suregada glomerulata (Euphorbiaceae) was found to inhibit rat small intestinal alpha-glucosidase. An examination of the extract afforded 20 iminosugars including one pyrrolidine and 19 piperidines. The structures of the 10 new compounds (11-20) were determined by NMR, and MS spectroscopic data analyses, and chemical correlations. The novelty of the identified compounds mainly stems from the loss of a hydroxy at C-4 and the presence of an 8-hydroxyoctyl side chain. Nine N-alkyl derivatives including N-methyl (1a, 8a, and 13a), N-butyl (1b, 2b, and 9b) and N,N-dimethyl (1c, 2c, and 9c) were synthesized. The compounds were tested for rat small intestinal a-glucosidase inhibitory activity. In total, 15 compounds, including compounds 11, 12, 15, and 19 and the three derivatives 8a, 9b, and 13a, showed inhibitory activity with IC50 values less than 40 mu M. In vivo results showed that total alkaloids of S. glomerulata (10 mg/kg) and four major iminosugars 1, 2, 3, and 9 (10 mg/kg) can lower the postprandial blood glucose level after sucrose and starch load in healthy male ICR mice. (C) 2013 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2013.07.048
  • 作为产物:
    描述:
    甲基溴化镁 、 tetra-(O-trimethylsilyl)-1-α-cyano-1-deoxynojirimycin 在 盐酸 作用下, 生成 2,6,7-trideoxy-2,6-imino-L-glycero-L-gulo-heptitol 、 α-7-deoxyhomonojirimycin
    参考文献:
    名称:
    Boeshagen; Geiger; Junge, Angewandte Chemie, 1981, vol. 93, # 9, p. 800 - 801
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • [EN] GLYCOSIDASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE GLYCOSIDASES ET LEURS UTILISATIONS
    申请人:ALECTOS THERAPEUTICS INC
    公开号:WO2014032184A1
    公开(公告)日:2014-03-06
    The invention provides compounds for inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    该发明提供了用于抑制糖苷酶的化合物,这些化合物的前药,以及包括这些化合物或这些化合物的前药的药物组合物。该发明还提供了用于治疗与O-GlcNAcase缺乏或过度表达、O-GlcNAc的积累或缺乏相关的疾病和障碍的方法。
  • GLYCOSIDASE INHIBITORS AND USES THEREOF
    申请人:Alectos Therapeutics Inc.
    公开号:US20150299122A1
    公开(公告)日:2015-10-22
    The invention provides compounds for inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    本发明提供了抑制糖苷酶的化合物,该化合物的前药,以及包括该化合物或该化合物的前药的制药组合物。本发明还提供了治疗与O-GlcNA酶的缺乏或过度表达、O-GlcNAc的积累或缺乏有关的疾病和障碍的方法。
  • TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES
    申请人:De Moor Olivier
    公开号:US20110237538A1
    公开(公告)日:2011-09-29
    Described are various compounds, in particular iminosugars, and methods for the treatment of proteostatic diseases, in particular lysosomal storage disorders. The compound may be a pharmacoperone of an enzyme selected from: (a) Acid alpha-glucosidase; (b) Acid beta-glucosidase; (c) glucocerebrosidase; (d) alpha-Galactosidase A; (e) Acid beta-galactosidase; (f) beta-Hexosaminidase A; (g) beta-Hexosaminidase B; (h) Acid sphingomyelinase; (i) Galactocerebrosidase; (j) Acid ceramidase; (k) Arylsulfatase A; (l) alpha-L-Iduronidase; (m) Iduronate-2-sulfatase; (n) Heparan N-sulfatase; (o) alpha-N-Acetylglucosaminidase; (p) Acetyl-CoA: alpha-glucosaminide N-acetyltransferase; (q) N-Acetylglucosamine-6-sulfate sulfatase; (r) N-Acetylgalactosamine-6-sulfate sulfatase; (s) Acid beta-galactosidase; (t) Arylsulfatase B; (u) beta-Glucuronidase; (v) Acid alpha-mannosidase; (w) Acid beta-mannosidase; (x) Acid alpha-L-fucosidase; (y) Sialidase; and (z) alpha-N-acetylgalactosaminidase.
  • US9181184B2
    申请人:——
    公开号:US9181184B2
    公开(公告)日:2015-11-10
  • Boeshagen; Geiger; Junge, Angewandte Chemie, 1981, vol. 93, # 9, p. 800 - 801
    作者:Boeshagen、Geiger、Junge
    DOI:——
    日期:——
查看更多